To test this hypothesis, two reported specific HDAC6 inhibitors (10 μM Ricolinostat, 10 μM ACY-738) were tested on a panel of IDH1 mutant glioma lines and showed high efficacy against these lines (Fig. 5D). Here, HDAC6 is linked to central nervous system cancer.